- Home
- SKYQ vs APRE Comparison
SKYQ vs APRE Comparison
Compare SKYQ & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYQ
- APRE
- Stock Information
- Founded
- SKYQ 2019
- APRE 2006
- Country
- SKYQ United States
- APRE United States
- Employees
- SKYQ N/A
- APRE N/A
- Industry
- SKYQ
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SKYQ
- APRE Health Care
- Exchange
- SKYQ NYSE
- APRE Nasdaq
- Market Cap
- SKYQ 20.3M
- APRE 21.2M
- IPO Year
- SKYQ N/A
- APRE 2019
- Fundamental
- Price
- SKYQ $0.88
- APRE $2.62
- Analyst Decision
- SKYQ
- APRE Strong Buy
- Analyst Count
- SKYQ 0
- APRE 2
- Target Price
- SKYQ N/A
- APRE $15.50
- AVG Volume (30 Days)
- SKYQ 80.6K
- APRE 35.7K
- Earning Date
- SKYQ 03-04-2025
- APRE 03-25-2025
- Dividend Yield
- SKYQ N/A
- APRE N/A
- EPS Growth
- SKYQ N/A
- APRE N/A
- EPS
- SKYQ N/A
- APRE N/A
- Revenue
- SKYQ $30,766,012.00
- APRE $1,310,839.00
- Revenue This Year
- SKYQ N/A
- APRE $134.21
- Revenue Next Year
- SKYQ N/A
- APRE N/A
- P/E Ratio
- SKYQ N/A
- APRE N/A
- Revenue Growth
- SKYQ N/A
- APRE 130.31
- 52 Week Low
- SKYQ $0.82
- APRE $2.15
- 52 Week High
- SKYQ $5.49
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- SKYQ N/A
- APRE 30.05
- Support Level
- SKYQ N/A
- APRE $2.59
- Resistance Level
- SKYQ N/A
- APRE $3.72
- Average True Range (ATR)
- SKYQ 0.00
- APRE 0.35
- MACD
- SKYQ 0.00
- APRE -0.13
- Stochastic Oscillator
- SKYQ 0.00
- APRE 1.41
About SKYQ SKY QUARRY INC
Sky Quarry Inc is a development-stage oil-producing and refining company. The company along with its subsidiaries is engaged in deploying technologies to facilitate the recycling of waste asphalt shingles and remediation of oil-saturated soils. The recycling and production of oil from asphalt shingles is expected to reduce the dependence on landfills for the disposal of waste and to also reduce dependence on foreign and domestic virgin crude oil extraction for industrial uses.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.